Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Coeptis Therapeutics Holdings Inc

COEP:NAQ

Coeptis Therapeutics Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.178
  • Today's Change-0.002 / -1.11%
  • Shares traded56.15k
  • 1 Year change-80.98%
  • Beta-0.9066
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen chimeric antigen receptor (CAR) T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells are genetically engineered to recognize cancer cells to target and destroy them.

  • Revenue in USD (TTM)0.00
  • Net income in USD-16.14m
  • Incorporated2022
  • Employees5.00
  • Location
    Coeptis Therapeutics Holdings Inc105 Bradford Road, Suite 420WEXFORD 15090United StatesUSA
  • Phone+1 (724) 934-6467
  • Fax+1 (302) 636-5454
  • Websitehttps://coeptistx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Silo Pharma Inc72.12k-3.45m4.66m3.00--0.6495--64.67-1.16-1.180.02421.600.0079----24,040.00-37.69-24.90-43.50-26.3991.9082.79-4,777.02-2,757.85----0.00--0.00--7.07------
Stemtech Corp5.37m-5.11m4.83m45.00------0.8998-0.0518-0.05180.0529-0.03591.338.3942.31---126.26------77.87---95.16--0.065-2.59----7.94--36.45------
CYANOTECH CORP23.82m-5.10m4.87m77.00--0.4563--0.2045-0.7549-0.75493.561.530.88952.0512.12309,389.60-19.04-3.46-29.60-4.4624.7234.54-21.41-3.580.3354-6.610.377---0.4616-5.24-53.11---6.42--
AgriFORCE Growing Systems Ltd57.60k-15.05m5.16m7.00--0.4074--89.59-5.81-5.810.00370.13430.0034--1.218,228.57-88.79-78.95-124.14-109.8617.86---26,121.49-243,182.501.24-1.280.0789------8.85--48.61--
Titan Pharmaceuticals Inc4.00k-5.46m5.17m4.00--1.30--1,293.64-6.59-6.590.00494.370.0016--0.17021,000.00-211.58-96.80-368.99-156.65-----136,525.00-406.26---309.960.00---66.97-51.1645.43---65.61--
Sonnet Biotherapeutics Holdings Inc55.89k-7.99m5.20m12.00--1.99--93.08-3.02-3.020.01440.50170.0071--0.08814,657.50-100.88---255.30-------14,287.67-----331.070.00---57.76--36.64------
Hoth Therapeutics Inc0.00-7.46m6.70m2.00--0.5565-----1.69-1.690.001.740.00----0.00-67.99-157.07-76.33-177.32------------0.00------31.01------
Integrated BioPharma, Inc.50.57m-116.00k6.86m141.00--0.362932.370.1357-0.0041-0.00411.670.62831.884.4510.76358,617.00-0.43115.54-0.569828.007.0912.09-0.22946.451.02-9.000.001---9.913.00-100.42---14.03--
Bon Natural Life Ltd29.52m4.60m6.95m96.000.35070.05791.260.23544.994.9932.1030.230.704515.275.19307,524.6010.8614.0413.6920.6829.9430.0015.4217.622.4130.540.09550.00-1.2922.32-26.3283.09-6.70--
Universe Pharmaceuticals Inc32.31m-6.16m6.95m225.00--0.027--0.2152-1.70-1.708.9110.910.57277.932.50143,594.40-10.925.31-14.347.0731.9346.26-19.086.252.43-28.050.12180.00-19.522.5329.46---21.17--
Bright Green Corp0.00-9.92m6.98m5.00--0.7076-----0.0538-0.05380.000.05190.00----0.00-47.48---72.55--------------0.0494------52.54------
Biofrontera Inc35.24m-13.51m7.10m85.00--0.5976--0.2013-5.29-5.2912.122.141.211.977.27414,623.50-46.20---113.24--47.75---38.33--1.46-3.530.0264--18.82---3,045.47------
Coeptis Therapeutics Holdings Inc0.00-16.14m7.15m5.00---------0.5143-0.51430.00-0.01110.00----0.00-284.35-37.29-709.12-38.23------------1.22------43.40------
CV Sciences Inc15.85m-2.53m8.08m42.00--3.22--0.5096-0.0157-0.01570.0980.01391.691.5525.35377,285.70-26.94-43.42-73.44-77.7546.0651.81-15.95-45.680.2530--0.0114---1.24-19.80133.96-20.87----
Data as of Sep 23 2024. Currency figures normalised to Coeptis Therapeutics Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

12.58%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Mar 20243.03m8.16%
Creative Planning LLCas of 31 Mar 2024645.10k1.74%
Meteora Capital LLCas of 31 Mar 2024446.25k1.20%
Geode Capital Management LLCas of 30 Jun 2024198.85k0.54%
The Vanguard Group, Inc.as of 31 Mar 2024108.71k0.29%
Cambridge Investment Research Advisors, Inc.as of 30 Jun 202456.15k0.15%
Arista Wealth Management LLCas of 31 Mar 202447.33k0.13%
Mint Tower Capital BVas of 31 Mar 202445.00k0.12%
Sea Otter Advisors LLCas of 31 Mar 202445.00k0.12%
Ionic Capital Management LLCas of 31 Mar 202445.00k0.12%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.